quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:55:58·48d
INSIDERFiling
Madrigal Pharmaceuticals Inc. logo

Chief Medical Officer Soergel David was granted 4,374 shares, increasing direct ownership by 58% to 11,919 units (SEC Form 4)

MDGL· Madrigal Pharmaceuticals Inc.
Health Care
Original source

Companies

  • MDGL
    Madrigal Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$964.00
  • Jan 6UpdateWolfe Research-
  • Nov 5UpdateCantor Fitzgerald-
  • Nov 3UpdateBofA Securities$445.00
  • Oct 15UpdateTruist$580.00
  • Sep 4UpdateH.C. Wainwright$500.00

Related

  • PR1d
    Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
  • PR2d
    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  • PR16d
    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.
  • PR35d
    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER48d
    EVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)
  • INSIDER48d
    President and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)
  • INSIDER48d
    General Counsel Kelley Shannon T was granted 4,017 shares and sold $155,498 worth of shares (360 units at $431.94), increasing direct ownership by 43% to 12,138 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022